A correlative study of homocysteine levels and dementia: an Indian perspective

Authors

  • Roshan Iqbal Department. of Neurology, JSS Medical College, Mysuru, Karnataka, India
  • S. Harsha Department. of Neurology, JSS Medical College, Mysuru, Karnataka, India
  • Nemichandra S. C. Department. of Neurology, JSS Medical College, Mysuru, Karnataka, India
  • Shasthara Paneyala Department. of Neurology, JSS Medical College, Mysuru, Karnataka, India
  • Vimala C. Colaco Department. of Neurology, JSS Medical College, Mysuru, Karnataka, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20213077

Keywords:

Homocysteine, Dementia, Small vessel disease, Vascular risk factors

Abstract

Background: The prevalence of dementia is increasing worldwide and with India experiencing an epidemiological transition with increasing ageing population, the prevalence in India is expected to double by 2030 adding to the already high burden of significant health care costs and caregiver fatigue. Indian population has a higher burden of elevated homocysteine levels due to multiple factors. However, studies correlating the homocysteine levels and severity of dementia in the Indian subcontinent is lacking. This study is aimed to analyse the diagnostic utility of serum total homocysteine in dementia and to examine the association between serum total homocysteine levels and severity of dementia.

Methods: This was a cross-sectional hospital-based study on patients attending neurology out-patient department who satisfied the DSM-V criteria. Each participant underwent an interview of general health and function followed by a standard assessment including medical history, physical and neurological examination as well as a neuropsychological battery.

Results: A total of 30 patients fulfilling the DSM-Vcriteria for Dementia were included in the study. Increasing S. Homocysteine levels were associated with lower neuropsychological compound scores with MMSE score of 20.78±2.98 and ACE-3 score of 77.40±5.60 in patients with Serum Homocysteine less than 22 Umoles/L and 18.85±2.50 and 75.55±5.06 respectively in patients with serum homocysteine levels above 22 Umoles/L. However, there was no statistically significant correlation between neurocognitive scores and serum homocysteine levels (p value 0.06 for MMSE and 0.19 for ACE-3). Also, no correlation was found between severity of dementia and serum homocysteine levels with p≥0.05 and Pearson’s correlation coefficient r=0.06.

Conclusions: This study shows no significant association between serum total homocysteine levels and severity of dementia. Thus, the association of homocysteine as an independent risk factor with the diagnosis and severity of dementia needs to be re-evaluated as it might undermine the multiple mechanisms underlying the pathogenesis of dementia.

Author Biographies

Roshan Iqbal, Department. of Neurology, JSS Medical College, Mysuru, Karnataka, India

Department of neurology, post graduate

S. Harsha, Department. of Neurology, JSS Medical College, Mysuru, Karnataka, India

Department of Neurology, Professor and Head of the Department

Nemichandra S. C., Department. of Neurology, JSS Medical College, Mysuru, Karnataka, India

Department of Neurology, Associate Professor

Shasthara Paneyala, Department. of Neurology, JSS Medical College, Mysuru, Karnataka, India

Department of Neurology, Assistant Professor

Vimala C. Colaco, Department. of Neurology, JSS Medical College, Mysuru, Karnataka, India

Department of neurology, post graduate

References

American Psychiatric Association: Diagnostic. https://scholar.google.com/scholar_lookup?title=Diagnostic+and+Statistical+Manual+of+Mental+Disorders&publication_year=2013&. Accessed on 25th July, 2020.

Alzheimer’s & Dementia Help | INDIA. Alzheimer’s Association. //www.alz.org/in/de mentia-alzheimers-en.asp. Accessed on 25th July, 2020.

Rius-Pérez S, Tormos AM, Pérez S, Taléns-Visconti R. Vascular pathology: Cause or effect in Alzheimer disease? Neurol Engl Ed. 2018;33(2):112-20.

Rosendorff C, Beeri MS, Silverman JM. Cardiovascular risk factors for Alzheimer’s disease. Am J Geriatr Cardiol. 2007;16(3):143-9.

Shenoy V, Mehendale V, Prabhu K, Shetty R, Rao P. Correlation of Serum Homocysteine Levels with the Severity of Coronary Artery Disease. Indian J Clin Biochem. 2014;29(3):339-44.

The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. https://www.researchgate.net/publication/326241237_The_current_status_of_homocystei ne_as_a_risk _factor_for_cardiovascular_disease_a_mini_review. Accessed on 25th July, 2020.

Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998 ;55(11):1449-55.

Prins ND, Den Heijer T, Hofman A, Koudstaal PJ, Jolles J, Clarke R, et al. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology. 2002;59(9):1375-80.

Hughes K, Ong C. Homocysteine, folate, vitamin B12, and cardiovascular risk in Indians, Malays, and Chinese in Singapore. J Epidemiol Community Health. 2000;54(1):31-4.

Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-38.

Touboul P-J, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim Carotid Intima-Media Thickness Consensus (2004–2006). Cerebrovasc Dis. 2007;23(1):75-80.

Crouse JR, Harpold GH, Kahl FR, Toole JF, McKinney WM. Evaluation of a scoring system for extracranial carotid atherosclerosis extent with B-mode ultrasound. Stroke [Internet]. 1986;17(2):270-5.

Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr. 2005;82(3):636-43.

Hooshmand B, Solomon A, Kåreholt I, Leiviskä J, Rusanen M, Ahtiluoto S, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology. 2010;75(16):1408-14.

Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett. 2006;580(13):2994-3005.

Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MMB. Total Homocysteine and Cognitive Decline in a Community-based Sample of Elderly Subjects: The Rotterdam Study. Am J Epidemiol. 1999;150(3):283-9.

Arioğul S, Cankurtaran M, Dağli N, Khalil M, Yavuz B. Vitamin B12, folate, homocysteine and dementia: are they really related? Arch Gerontol Geriatr. 2005;40(2):139-46.

Chen S, Honda T, Ohara T, Hata J, Hirakawa Y, Yoshida D, et al. Serum homocysteine and risk of dementia in Japan. J Neurol Neurosurg Psychiatry. 2020;91(5):540-6.

Xu W-H. Large artery: an important target for cerebral small vessel diseases. Ann Transl Med. 2014;2(8):78.

Kalaria RN. Small Vessel Disease and Alzheimer’s Dementia: Pathological Considerations. Cerebrovasc Dis. 2002;13(2):48-52.

Moretti R, Caruso P. The Controversial Role of Homocysteine in Neurology: From Labs to Clinical Practice. Int J Mol Sci. 2019;20(1).

Gunstad J, Bausserman L, Paul RH, Tate DF, Hoth K, Poppas A, et al. C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease. J Clin Neurosci Off J Neurosurg Soc Australas. 2006;13(5):540-6.

Li Y, Wang L, Zhang W, Fang Y, Niu X. No association between elevated homocysteine levels and carotid atherosclerosis in a rural population in China. Stroke Vasc Neurol. 2016;1(4):154-60.

Potter K, Hankey GJ, Green DJ, Eikelboom J, Jamrozik K, Arnolda LF. The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. BMC Cardiovasc Disord. 2008;8:24.

S Z, Bp M, P B, Pg K, C M, R W, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006;47(6).

Sundström J, Sullivan L, D’Agostino RB, Jacques PF, Selhub J, Rosenberg IH, et al. Plasma Homocysteine, Hypertension Incidence, and Blood Pressure Tracking. Hypertension. 2003;42(6):1100-5.

Sadeghian S, Fallahi F, Salarifar M, Davoodi G, Mahmoodian M, Fallah N, et al. Homocysteine, vitamin B12 and folate levels in premature coronary artery disease. BMC Cardiovasc Disord. 2006;6(1):38.

Raina SK, Chahal JS, Kaur N. Correlation between homocysteine and Vitamin B12 levels: A post-hoc analysis from North-West India. Int J Health Allied Sci. 2015;4(2):115.

Takenoshita S, Terada S, Yoshida H, Yamaguchi M, Yabe M, Imai N, et al. Validation of Addenbrooke’s cognitive examination III for detecting mild cognitive impairment and dementia in Japan. BMC Geriatr. 2019;19.

Quental NBM, Brucki SMD, Bueno OFA. Visuospatial function in early Alzheimer’s disease--the use of the Visual Object and Space Perception (VOSP) battery. PloS One. 2013;8(7):e68398.

Jiang Y, Wang Y, Yuan Z, Xu K, Zhang K, Zhu Z, et al. Total Cerebral Small Vessel Disease Burden Is Related to Worse Performance on the Mini-Mental State Examination and Incident Dementia: A Prospective 5-Year Follow-Up. J Alzheimers Dis. 2019;69(1):253-62.

Yilmaz P, Ikram MK, Niessen WJ, Ikram MA, Vernooij MW. Practical Small Vessel Disease Score Relates to Stroke, Dementia, and Death. Stroke. 2018;49(12):2857-65.

Rensma SP, van Sloten TT, Launer LJ, Stehouwer CDA. Cerebral small vessel disease and risk of incident stroke, dementia and depression, and all-cause mortality: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;90:164-73.

McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A Controlled Trial of Homocysteine Lowering and Cognitive Performance. N Engl J Med. 2006;354(26):2764-72.

Kwok T, Lee J, Law CB, Pan PC, Yung CY, Choi KC, et al. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. Clin Nutr. 2011;30(3):297-302.

Ford AH, Almeida OP. Effect of homocysteine lowering treatment on cognitive function: a systematic review and meta-analysis of randomized controlled trials. J Alzheimers Dis JAD. 2012;29(1):133-49.

Oijen M van, Jong FJ de, Witteman JCM, Hofman A, Koudstaal PJ, Breteler MMB. Atherosclerosis and risk for dementia. Ann Neurol. 2007;61(5):403-10.

Mathiesen EB, Waterloo K, Joakimsen O, Bakke SJ, Jacobsen EA, Bønaa KH. Reduced neuropsychological test performance in asymptomatic carotid stenosis: The Tromsø Study. Neurology. 2004;62(5):695-701.

Wang X, Jackson DC, Mitchell CC, Varghese T, Wilbrand SM, Rocque BG, et al. Classification of Symptomatic and Asymptomatic Patients with and without Cognitive Decline using Non-invasive Carotid Plaque Strain Indices as Biomarkers. Ultrasound Med Biol. 2016;42(4):909-18.

Downloads

Published

2021-07-28

How to Cite

Iqbal, R., Harsha, S., C., N. S., Paneyala, S., & Colaco, V. C. (2021). A correlative study of homocysteine levels and dementia: an Indian perspective. International Journal of Research in Medical Sciences, 9(8), 2330–2338. https://doi.org/10.18203/2320-6012.ijrms20213077

Issue

Section

Original Research Articles